

Neonatal Seizures

Etiologies

Most seizures in neonates are acute provoked seizures; initial evaluations should focus on identifying underlying causes concurrent with treatment of seizures. Because seizures in neonates are often a sign of underlying brain pathology or injury, suspected or confirmed seizures should be treated as medical emergencies. If the infant is not already in the NICU, transfer should occur promptly.

- HIE
- Stroke
- Intracranial hemorrhage
- Acute metabolic derangements (e.g., hypoglycemia, hypocalcemia, hyponatremia, hypomagnesemia)
- Infection (e.g., bacterial sepsis/meningitis, HSV)
- Drug withdrawal or intoxication
- Neonatal-onset epilepsy (~20%) – underlying etiologies include cortical malformations, inborn errors of metabolism (IEM), and other genetic conditions

Clinical Features

A large proportion of neonatal seizures do not have observable clinical manifestations. Newborns are less likely to display motor correlates due to the immaturity of motor tracts and relative lack of myelination at this stage in development. Newborns may also display non-epileptic paroxysmal movements, such as jitteriness or sleep myoclonus, which can be falsely categorized as seizures.

EEG is necessary to definitively diagnose neonatal seizures. **Contact Pediatric Neurology as soon as there is concern for possible neonatal seizures; cEEG can be initiated even before the consult team sees the baby.** While awaiting EEG, certain clinical features may help distinguish between seizures and non-epileptic movements.

Probable seizures:

- Stereotyped, rhythmic clonic movements that cannot be suppressed by restraint or repositioning.

Unlikely to be seizures:

- Jitteriness or tremors that are stimulus-sensitive or resolve with repositioning.
- Movements that are non-stereotyped or random.

Other types of paroxysmal events, such as tonic posturing, eye movements, or automatisms cannot reliably be diagnosed as seizure or non-seizure without EEG.

Diagnostic Workup

The diagnostic workup for neonatal seizures should start by assessing for acute provoking causes, starting with reversible causes.

- Check serum electrolytes (including Ca and Mg) and serum glucose, and *correct any abnormalities*
- Head ultrasound as soon as possible while awaiting MRI
- Brain MRI (discuss with neurology team whether MRS, MRA, and/or MRV is indicated)
- Sepsis workup including LP, if concern for infection
- Placental pathology (ask OB team to send placenta for pathology)
- Consider toxicology screening (urine tox, meconium tox)
- If concern for IEM*, consider sending blood gas with lactate, labs (serum amino acids, urine organic acids, serum ammonia, serum lactate/pyruvate, acylcarnitine profile, very-long-chain fatty acids) and consulting Genomic Medicine
- If MRI does not reveal a cause of seizures, consider consulting Genomic Medicine to evaluate for genetic causes of seizures (incl. *KCNQ2* variants)

**Consider IEM in the following settings:*

- *Encephalopathy with poor feeding and lethargy following an initial symptom-free period of a few to several days*
- *Seizures refractory to conventional treatment*
- *Seizures associated with progressive deterioration of clinical status and worsening of EEG background pattern*
- *Myoclonic seizure semiology*

Management

Neuroprotective measures

Care should be taken to maintain normothermia (unless undergoing therapeutic hypothermia for presumed HIE), normal ventilation (with strict avoidance of hypocarbia) and oxygenation, normal blood pressure, normoglycemia, and normal serum electrolyte levels.

Neurology Consultation

Consult Pediatric Neurology for all neonates with concern for seizures. The NICU team and neurology can discuss together individual patient factors that might warrant alternatives to the pathway below, as well as consideration of additional or adjunctive treatments (such as pyridoxine) for refractory seizures.


Pharmacotherapy

See Management Algorithm on next page for recommended medications and dosages. Medical management of neonatal seizures should always be done in collaboration with the Child Neurology team.

Notes regarding pharmacotherapy:

1. Antiseizure medication loading doses given for active seizures should be ordered STAT.
2. Goal is to start infusing the loading dose within 10 minutes of seizure identification.
3. While the current loading dose is infusing, order the next antiseizure medication/loading dose in the treatment algorithm STAT so that it is immediately available if seizures continue.
4. Notify Neurology immediately upon completion of the loading dose; RN to mark medication administration on EEG.
5. Neurology reviews EEG for response.
6. Goal: EEG assessment/feedback within 15 minutes of notification.
7. If electrographic seizures persist, administer the next loading dose/treatment per the seizure treatment algorithm.

Seizure Treatment Algorithm



NICU EEG Order & Communication Workflow:

- Requests for cEEG hookups should be ordered in Epic AND communicated by phone/TigerText to the on-call Pediatric Neurology resident.
 - Both are needed for the cEEG to be initiated
 - On-call Pediatric Neurology resident will communicate with EEG Tech to ensure request is received and triaged as priority.
- EEG Tech will initiate cEEG as early as possible
 - If delay is anticipated due to queue of cEEG hookups pending, NICU may choose to use aEEG in interim
 - Once cEEG initiated, EEG Tech will notify on-call Peds EEG reader
- Initial EEG interpretation will be completed within 1 hour of cEEG initiation
 - Peds EEG reader will communicate result to on-call Pediatric Neurology resident
 - Pediatric Neurology resident will contact NICU to share EEG results and discuss next steps in patient care as priority.
 - To contact the appropriate NICU provider, Ped Neuro Provider will:
 - Call NICU front desk at x33050 and ask to speak to the NICU Fellow (NICU HUSC will Vocera “Neonatal Fellow” to pick up extension)
 - If NICU fellow is unavailable, call NICU Front desk x33050 and request to speak to the NICU Attending (NICU HUSC will Vocera “Neonatal Attending” to pick up extension)
- Subsequent EEG checks will be at frequency determined by clinical need
 - All cEEGs are screened by EEG technologists day & night
 - If no seizures and reassuring EEG, reviewed by Peds EEG reader at minimum twice each day with results communicated to on-call Pediatric Neurology resident, and a written report daily.
 - If seizures identified on EEG, EEG checks will be as each step of the treatment pathway is completed (e.g., after first drug is given, after 2nd drug is given, etc.)
 - Bedside providers to designate when drugs are given by pushing the button and saying out loud which drug is starting at that time
 - Updates on EEG findings will be relayed by the on-call Pediatric Neurology resident as a priority, to discuss with the NICU in combination with treatment recommendations
- Requests for additional EEG checks
 - In addition to EEG checks as above, clinical changes or suspicious events may prompt request for additional EEG checks.
 - Each suspicious clinical event should be marked at the bedside by pushing the button and stating out loud the nature of the event in question. Pushing the button will flag the event for the attention of the screening tech (most immediately) and the Peds EEG reader (during their periodic reviews of the record).

- 
- If an event is suspected to be seizure, the technologist contacts the Peds EEG reader, who will communicate all results through the Pediatric Neurology consult team.

References

- Glass, H. C., et al. (2013). Amplitude-integrated electro-encephalography: the child neurologist's perspective. J Child Neurol 28(10): 1342-1350.
- Painter, M. J., et al. (1999). Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med 341(7): 485-489.
- Pressler, R. M., et al. (2023). Treatment of seizures in the neonate: Guidelines and consensus-based recommendations-Special report from the ILAE Task Force on Neonatal Seizures. Epilepsia 64(10): 2550-2570.
- Pressler, R. M., et al. (2021). The ILAE classification of seizures and the epilepsies: Modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures. Epilepsia 62(3): 615-628.
- Sharpe, C., et al. (2020). Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial. Pediatrics 145(6).
- Wusthoff, C.J., et al. (2025). The American Clinical Neurophysiology Society Guideline on Indications for Continuous Electroencephalography Monitoring in Neonates. J. Clin. Neurophysiol. 42(1): 1-11.
- Shellhaas, R. Clinical features, evaluation, and diagnosis of neonatal seizures. In: UpToDate, Connor RF (Ed), Wolters Kluwer. (Accessed on December 4, 2024.)
- World Health Organization. (2011). Guidelines on neonatal seizures. Geneva, World Health Organization.
- Zuberi, S. M., et al. (2022). ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 63(6): 1349-1397.

Medical Legal Disclaimer:

Welcome to the UC Davis Health, Department of Pediatrics, Clinical Practice Guidelines Website. All health and health-related information contained within the Site is intended chiefly for use as a resource by the Department's clinical staff and trainees in the course and scope of their approved functions/activities (although it may be accessible by others via the internet). This Site is not intended to be used as a substitute for the exercise of independent professional judgment. These clinical pathways are intended to be a guide for practitioners and may need to be adapted for each specific patient based on the practitioner's professional judgment, consideration of any unique circumstances, the needs of each patient and their family, and/or the availability of various resources at the health care institution where the patient is located. Efforts are made to ensure that the material within this Site is accurate and timely but is provided without warranty for quality or accuracy. The Regents of the University of California; University of California, Davis; University of California, Davis, Health nor any other contributing author is responsible for any errors or omissions in any information provided or the results obtained from the use of such information. Some pages within this Site, for the convenience of users, are linked to or may refer to websites not managed by UC Davis Health. UC Davis Health does not control or take responsibility for the content of these websites, and the views and opinions of the documents in this Site do not imply endorsement or credibility of the service, information or product offered through the linked sites by UC Davis Health. UC Davis Health provides limited personal permission to use the Site. This Site is limited in that you may not:

- Use, download or print material from this site for commercial use such as selling, creating course packets, or posting information on another website.
- Change or delete propriety notices from material downloaded or printed from it. · Post or transmit any unlawful, threatening, libelous, defamatory, obscene, scandalous, inflammatory, pornographic, or profane material, any propriety information belonging to others or any material that could be deemed as or encourage criminal activity, give rise to civil liability, or otherwise violate the law.
- Use the Site in a manner contrary to any applicable law.

You should assume that everything you see or read on this Site is copyrighted by University of California or others unless otherwise noted. You may download information from this Site as long as it is not used for commercial purposes, and you retain the proprietary notices. You may not use, modify, make multiple copies, or distribute or transmit the contents of this Site for public or commercial purposes without the express consent of UC Davis Health.